- Home
- FI vs GILD Comparison
FI vs GILD Comparison
Compare FI & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FI
- GILD
- Stock Information
- Founded
- FI 1984
- GILD 1987
- Country
- FI United States
- GILD United States
- Employees
- FI N/A
- GILD N/A
- Industry
- FI Business Services
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FI Consumer Discretionary
- GILD Health Care
- Exchange
- FI Nasdaq
- GILD Nasdaq
- Market Cap
- FI 116.3B
- GILD 129.9B
- IPO Year
- FI 1986
- GILD 1992
- Fundamental
- Price
- FI $184.06
- GILD $96.91
- Analyst Decision
- FI Strong Buy
- GILD Buy
- Analyst Count
- FI 24
- GILD 25
- Target Price
- FI $237.61
- GILD $109.00
- AVG Volume (30 Days)
- FI 4.2M
- GILD 8.7M
- Earning Date
- FI 04-24-2025
- GILD 04-24-2025
- Dividend Yield
- FI N/A
- GILD 3.26%
- EPS Growth
- FI 5.73
- GILD 1118.07
- EPS
- FI 5.65
- GILD 4.73
- Revenue
- FI $20,703,000,000.00
- GILD $28,735,000,000.00
- Revenue This Year
- FI $4.64
- GILD $1.88
- Revenue Next Year
- FI $8.75
- GILD $3.95
- P/E Ratio
- FI $32.54
- GILD $20.47
- Revenue Growth
- FI 6.56
- GILD 4.68
- 52 Week Low
- FI $146.25
- GILD $62.07
- 52 Week High
- FI $238.59
- GILD $119.96
- Technical
- Relative Strength Index (RSI)
- FI 38.92
- GILD 34.47
- Support Level
- FI $181.75
- GILD $95.30
- Resistance Level
- FI $186.83
- GILD $107.17
- Average True Range (ATR)
- FI 6.19
- GILD 3.66
- MACD
- FI -0.12
- GILD -0.73
- Stochastic Oscillator
- FI 17.28
- GILD 24.95
About FI Fiserv Inc.
Fiserv is a leading provider of core processing and complementary services, such as electronic funds transfer, payment processing, and loan processing, for US banks and credit unions, with a focus on small and midsize banks. Through the merger with First Data in 2019, Fiserv also provides payment processing services for merchants. About 10% of the company's revenue is generated internationally.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).